Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Metformin Therapy in HCV Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02972723
Recruitment Status : Completed
First Posted : November 23, 2016
Last Update Posted : November 23, 2016
Information provided by (Responsible Party):
Nottingham University Hospitals NHS Trust

Brief Summary:

Hepatitis C virus infection (HCV) is a major cause of cirrhosis and death from liver disease worldwide. Current therapy for HCV with interferon based therapies results in cure rates of around 5055% which leaves a significant number of patients without effective therapy. HCV induces (can bring on) insulin resistance and insulin resistance is a factor known to reduce the response to antiHCV therapy. This finding stimulated initial studies looking at agents that may reduce insulin resistance as additional therapy in HCV infection.

A study using metformin in addition to interferon and ribavirin showed a nonsignificant increase in cure rates (53% vs. 42%), but this was limited to patients with type 1 infection AND demonstrable insulin resistance. The assumption was made that the potential effect of metformin was likely to be on insulin resistance and thus by modulating this enhances response. The investigators (Prof M Harris, University of Leeds) have data (currently unpublished)suggesting that metformin may have an antiviral effect independent of its effect on insulin resistance, thus raising the possibility that metformin may have a direct antiviral effect in vivo. Given that the development of specific antiHCV agents which target viral proteins such as its polymerase and protease are in trial development but have so far proved either highly toxic or are likely to have a huge cost there is considerable rationale for looking at alternative potential antiHCV agents and in this context metformin is cheap, readily available and has an excellent safety profile. This pilot study therefore addresses the question "Does metformin therapy result in a significant drop in HCV viral load in chronically infected patients?"

Condition or disease Intervention/treatment Phase
Chronic Hepatitis C Infection Drug: Metformin Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: A Study of the Antiviral Activity of Metformin as an Anti-Hepatitis C Virus Agent in Patients With Chronic Hepatitis C Virus Infection
Study Start Date : March 2011
Actual Primary Completion Date : September 2011
Actual Study Completion Date : December 2011

Arm Intervention/treatment
Experimental: Metformin therapy, single arm
Open label trial, participants will be expected to take Metformin twice a day for 2 weeks
Drug: Metformin
Oral Metformin 1g bd. (total = 2g per day) for 14 days
Other Name: Glucophage

Primary Outcome Measures :
  1. Drop of viral load by at least 1 log in patients receiving Metformin [ Time Frame: 14 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult Males and Females (18-70 yrs old) able to give consent
  • Chronic hepatitis C virus infection
  • Women of child bearing potential (who have a negative pregnancy test) must agree to use methods of medically acceptable forms of contraception during the study; (e.g.intra-uterine device (IUD) or a double-barrier method of oral contraception with condom)

Exclusion Criteria:

  • Type 2 diabetes.
  • Patients with impaired renal function.
  • Decompensated liver cirrhosis (stable patients with cirrhosis would be eligible).
  • Patients who in the opinion of the Investigator are considered unsuitable.
  • Pregnant females.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02972723

Layout table for location information
United Kingdom
Secondary care Hepatitis clinic at Nottingham University Hospital
Nottingham, United Kingdom, NG7 2UH
Sponsors and Collaborators
Nottingham University Hospitals NHS Trust
Layout table for investigator information
Principal Investigator: Stephen Dr Ryder Nottingham University Hospitals NHS Trust
Layout table for additonal information
Responsible Party: Nottingham University Hospitals NHS Trust Identifier: NCT02972723    
Other Study ID Numbers: 10ID003
2010-022850-18 ( EudraCT Number )
First Posted: November 23, 2016    Key Record Dates
Last Update Posted: November 23, 2016
Last Verified: November 2016
Keywords provided by Nottingham University Hospitals NHS Trust:
Metformin Therapy in HCV
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Hepatitis, Chronic
Disease Attributes
Pathologic Processes
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Blood-Borne Infections
Flaviviridae Infections
Chronic Disease
Hypoglycemic Agents
Physiological Effects of Drugs